ClinicalTrials.gg
Active, not recruitingNCT06738017Updated May 6, 2026

Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants

A Phase 1 interventional study of BMN 349 and Placebo in Alpha 1-Antitrypsin Deficiency, sponsored by BioMarin Pharmaceutical. Active, not recruiting at 7 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by BioMarin Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.

Enrollment
53rd of 55
6 · median 30
Started
2025
with 3 others
Phase 1
10 of 81
2 open now
Primary completion
2026-08
later than 1 of 20 live
Registered
76th of 81
by date

Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 53rd largest by enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 in phase 1, reaches primary completion later than 1 of the 20 other live ones, and was the 76th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the safety and tolerability of a single oral dose of BMN 349 in participants with PiZZ or PiMZ/MASH.

Primary outcome measures include incidence of any adverse events (including serious adverse events, dose limit toxicities, and adverse events of special interest), incidence of any laboratory test abnormalities, incidence of lung function test abnormalities and 12-lead ECG parameters.

Participants will receive a single dose of either BMN 349 or placebo and then monitored for safety and tolerability.

03

Conditions studied

  • Alpha 1-Antitrypsin Deficiency

Keywords

  • 349
  • 349-102
  • AATD
  • MASH
  • PiZZ
  • PiMZ
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmation of PiZZ or PiMZ genotype
  • Females and males, of any race, 18 to 75 years of age
  • Nonsmokers, defined as not using tobacco or nicotine-containing products for at least 6 months prior to Screening

Exclusion criteria

Exclusion Criteria:

  • (INR) > 1.2
  • (ALT) and aspartate aminotransferase (AST) levels > 125 U/L
  • Current or recent use of AAT augmentation therapy
  • Participants with recent (last 3 months) diagnosis of pneumonia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
6 participants (actual)

Study arms

  • Other
    Group A (PiZZ)

    5:1 (349:Placebo)

    Drug: BMN 349 · Drug: Placebo

  • Other
    Group B (PiMZ)

    5:1 (349:Placebo)

    Drug: BMN 349 · Drug: Placebo

Interventions

  • DrugBMN 349

    250mg oral tablet

  • DrugPlacebo

    250mg oral tablet

06

What researchers measure

Primary outcomes

  1. Participant Adverse Events, Serious Adverse Events, Dose Limit Toxicities, Adverse Event of Special Interests, abnormal laboratory tests, abnormal pulmonary function tests, and 12-lead ECG parameters

    Number of participant AEs, SAEs, DLTs, AESIs per physician's assessment, abnormal laboratory tests through whole blood samples, abnormal pulmonary function spirometry tests, and 12-lead ECG parameters changes from baseline following a single oral dose of BMN 349

    Time frame: 78 days

Secondary outcomes

  1. C max

    Maximum observed plasma concentration

    Time frame: 78 days

  2. AUC 0-t

    Area under the concentration-time curve from time 0 to the last measurable concentration

    Time frame: 78 days

  3. AUC 0-inf

    Area under the concentration-time curve from time 0 to infinity

    Time frame: 78 days

  4. CL/F

    Apparent total body clearance after oral dosing

    Time frame: 78 days

  5. T max

    Time to reach maximum concentration

    Time frame: 78 days

  6. t 1/2

    Terminal half-life in plasma

    Time frame: 78 days

  7. Vz/F

    Apparent volume of distribution during terminal phase

    Time frame: 78 days

  8. Assess functional activity of circulating Alpha1 AntiTrypsin in participants

    Changes in participant circulating AAT through whole blood samples following a single dose of BMN 349

    Time frame: 78 days

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Aug 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 17, 2024
StartActual
Feb 21, 2025
Primary completionEst.
Aug 19, 2026
CompletionEst.
Aug 19, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06738017
Responsible party
Sponsor
First posted
Dec 17, 2024
Start date
Feb 21, 2025
Primary completion
Aug 19, 2026 (estimated)
Completion
Aug 19, 2026 (estimated)
Last update
May 6, 2026

Study contacts

Medical Director, MD
study director · BioMarin Pharmaceutical

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion